免疫療法の世界市場：予測（2022年～2028年）

世界の免疫療法の市場規模は、2021年から2027年の予測期間中に、13.8％のCAGRで成長すると予想されています。市場の成長を後押しする主な要因には、成人の自己免疫疾患の有病率の増加、がんの研究および資金調達への投資の増加、免疫療法の承認に起因するモノクローナル抗体の生産増加、免疫療法の承認、技術開発などが挙げられます。一方で、がん免疫療法の高価格や、政府の厳しい規制、副作用の懸念などが市場の成長を抑制する可能性があります。

当レポートでは、世界の免疫療法市場を調査しており、市場の概要、市場の促進要因・抑制要因の分析、タイプ・用途・エンドユーザー・地域別の分析、競合情勢、さらに主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向

第3章 競合情勢

• 主要企業分析
• 主要戦略分析

第4章 市場決定要因

• 促進要因
• 抑制要因
• 機会

第5章 市場セグメンテーション

• 世界の免疫療法市場：タイプ別
  • モノクローナル抗体
  • がんワクチン
  • 自己免疫チェックポイント阻害剤
  • インターロイキン・インターフェロン（サイトカイニン）
  • その他
• 世界の免疫療法市場：用途別
  • がん
  • 自己免疫疾患・炎症性疾患
  • 感染症
  • その他
• 世界の免疫療法市場：エンドユーザー別
  • 病院
  • 診断センター
  • その他

第6章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 世界のその他の地域

第7章 企業プロファイル

• Advaxis, Inc.
• AbbVie Inc.
• AstraZeneca PLC
• Adaptimmune Therapeutics plc.
• Agenus, Inc.
• Atara Biotherapeutics, Inc.
• BellicumPhamaceuticals, Inc.
• Bristol-Myers Squibb Company
• bluebird bio, Inc.
• Chinook Therapeutics, Inc.
• Celldex Therapeutics, Inc.
• CytomX Therapeutics, Inc.
• Gilead Sciences, Inc.
• Incyte Corp.
• Johnson & Johnson Services, Inc.
• Jounce Therapeutics, Inc.
• MacroGenics, Inc.
• Novartis AG
• Merck & Co., Inc.,
• Xencor, Inc.
• Ziopharm Oncology, Inc.

LIST OF TABLES

• 1. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 2. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 3. GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL AUTOIMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 5. GLOBAL INTERFERON AND INTERLEUKINS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 7. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
• 8. GLOBAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 9. GLOBAL AUTOIMMUNE AND INFLAMMATORY DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 10. GLOBAL INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 12. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 13. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 14. GLOBAL DIAGNOSTIC CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 15. GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 16. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
• 17. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 18. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 19. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
• 20. NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 21. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 22. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 23. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
• 24. EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 25. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 26. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 27. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
• 28. ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 29. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
• 30. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
• 31. REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL IMMUNOTHERAPY MARKET SHARE BY TYPE, 2020 VS 2027 (%)
• 2. GLOBAL IMMUNOTHERAPY MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
• 3. GLOBAL IMMUNOTHERAPY MARKET SHARE BY END-USER, 2020 VS 2027 (%)
• 4. GLOBAL IMMUNOTHERAPY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 6. GLOBAL AUTOIMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 7. GLOBAL INTERFERON AND INTERLEUKINS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 8. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 9. GLOBAL CANCER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 10. GLOBAL AUTOIMMUNE AND INFLAMMATORY DISEASES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 11. GLOBAL INFECTIOUS DISEASES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 12. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 13. GLOBAL HOSPITALS MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 14. GLOBAL DIAGNOSTIC CENTRES MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 15. GLOBAL OTHER MARKET SHARE, BY GEOGRAPHY 2020-2027($ MILLION)
• 16. US IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 17. CANADA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 18. UK IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 19. FRANCE IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 20. GERMANY IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 21. ITALY IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 22. SPAIN IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 23. REST OF EUROPE IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 24. ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 25. INDIA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 26. CHINA IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 27. JAPAN IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)
• 28. REST OF ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION)

29. REST OF THE WORLD IMMUNOTHERAPY MARKET SIZE, 2020-2027 ($ MILLION))

Global Immunotherapy Market By Type (Monoclonal Antibodies, Cancer Vaccines, Autoimmune Checkpoint Inhibitors, Cytokinin's, & Other) By Application (Cancer, Autoimmune And Inflammatory Diseases, Infectious Diseases and Other) By End-User (Hospitals, Diagnostic Centers And Other) - Global Industry Share, Growth, Competitive Analysis And Forecast, 2021-2027 ($ Million)

The global immunotherapy market is growing at a CAGR of 13.8% during the forecast period (2021-2027). The major factors that are augmenting the growth of the immunotherapy market includes increasing prevalence of auto-immune diseases among adults and increasing investments in research and funding of cancer. Further due to the approval of immunotherapy for cancer treatment increasing monoclonal body production, inauguration of treatment facilities, approvals for immunotherapies, and technological development among others are also estimated to be the prime factors that are contributing significantly towards the growth of the market. For instance, in November 2019, Novartis inaugurated new manufacturing facility therapies for cell and gene at Stein, Switzerland. The global head of Novartis technical operations and member of the Novartis executive committee highlighted that this is another investment in the production of development related to cell-based therapies through which a prospective change could be there in lives of patients. Additionally, manufacturing area also facilitates production of solid dosage forms that includes tablets and capsules.

However, there are certain factors that are hampering the growth of the market. The high cost of cancer immunotherapies, strict rules and regulations relating with government policies in some region, manufacturing process related complexities, concern regarding side effects, are the major factors constraints that are hindering the growth of the global immunotherapy market across the globe.

Segmental Outlook

The market is segmented based on type, applications, and end-user. By type, the market is segmented into monoclonal antibodies, cancer vaccines, autoimmune checkpoint inhibitors, cytokinin's, & other. Further, based on the application segment, the market is segmented into cancer, autoimmune and inflammatory diseases, infectious diseases and other. Based on the end-user segment the market is segmented into hospitals, diagnostic centers and other.

Global Immunotherapy Market Share End-User, 2020 (%)

Global Immunotherapy Market Share End-User

By end-user, hospital segment held major market share in 2020. The high share of the segment is attributed to the high access of hospitals for treatment of chronic diseases. Most number of hospitals, especially in the cases related to cancer immunotherapy that center indicative conditions. The hospitals offer treatments in order to tackle a patient's own immune system for fighting the disease cancer. With the support of cancer vaccines, cellular therapies along with experimental drugs enhances the immune system to fight cancer. For instance, Northside Hospital Cancer Institute (NHCI) in the US has been offering immunotherapy since a longer period in the form of allogeneic stem cell transplantation. Through, this process the donor's blood is transplanted into a patient in order to cure aggressive cancer related to blood. Further, due to this transplant it acts for the first definitive proof for the human immune system's capacity regarding the curing of cancer.

Regional Outlooks

Global immunotherapy market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is estimated to be one of the leading regions in the global immunotherapy market. Some factors that are boosting the market growth in North America are growing pervasiveness of cancer along with autoimmune diseases, increasing demand for safe and secure therapies related to cancer, rising acquiescence from the FDA. Asia Pacific is estimated to exhibit the remarkable growth during the forecast period 2021-2027.

Global Immunotherapy Market Growth, by Region 2021-2027

Global Immunotherapy Market Growth, by Region

Asia-Pacific will have Considerable Growth in the Global Immunotherapy Market

Asia-Pacific region is expected to witness significant growth opportunity for the market. The increasing development related to technology in healthcare, vast patient population, increased expenditure in healthcare. Additionally, growing demand for new and advanced methods for treatment in countries such as India and South Korea further driving the regional market. The countries in Asia-Pacific region are also ongoing clinical trials along with FDA approvals for new molecule drug along with combination of therapies are expected to boost the treatment of tumors through immunotherapies. Further, the presence of market players with prime investment in the market, that includes AstraZeneca, Merck & Co., Inc. and Pfizer, Inc. are expanding the growth of the market in the region.

Market Players Outlook

Key players of the global immunotherapy market include AbbVie Inc, AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc. These players are different growth strategies such as mergers & acquisitions, partnerships, new product launches, and geographical expansion among others to remain competitive in the market place.

In August 2020, Bristol-Myers Squibb Co. Canada highlighted health Canada's approval of OPDIVO (nivolumab) along with YERVOY (ipilimumab) including limited chemotherapy. Regarding to the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The immune oncology will play a vital role in activating the body's own immune system in order to support recognize along with attack cancer cells. In September 2019, AstraZeneca's Imfinzi is considered as first immunotherapy to give significant survival benefit along with improved, durable responses in small cell lung cancer in extensive stage with the risk of death decreased to 27.0%. AstraZeneca presented detailing related to the results from phase III CASPIAN trial at the presidential symposium of the IASLC 2019 world conference on lung cancer. This showed a remarkable enhancement in overall survival (OS) in patients' .Imfinzi in combination with four cycles of standard-of-care (SoC) chemotherapy. SoC was consisted up to six cycle of chemotherapy along with optional prophylactic cranial irradiation (PCI).

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global immunotherapy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1.1. Overview
  • 3.1.1.2. Financial Analysis
  • 3.1.1.3. SWOT Analysis
  • 3.1.1.4. Recent Developments
• 3.2 Key Strategy Analysis

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Immunotherapy Market by Type
  • 5.1.1. Monoclonal Antibodies
  • 5.1.2. Cancer Vaccines
  • 5.1.3. Autoimmune Checkpoint Inhibitors
  • 5.1.4. Interleukins and Interferons (Cytokinins)
  • 5.1.5. . Other
• 5.2. Global Immunotherapy Market by Application
  • 5.2.1. Cancer
  • 5.2.2. Autoimmune and Inflammatory Diseases
  • 5.2.3. Infectious Diseases
  • 5.2.4. Other
• 5.3. Global Immunotherapy Market by End-User
  • 5.3.1. Hospitals
  • 5.3.2. Diagnostic Centers
  • 5.3.3. Other

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Advaxis, Inc.
• 7.2. AbbVie Inc.
• 7.3. AstraZeneca PLC
• 7.4. Adaptimmune Therapeutics plc.
• 7.5. Agenus, Inc.
• 7.6. Atara Biotherapeutics, Inc.
• 7.7. BellicumPhamaceuticals, Inc.
• 7.8. Bristol-Myers Squibb Company
• 7.9. bluebird bio, Inc.
• 7.10. Chinook Therapeutics, Inc.
• 7.11. Celldex Therapeutics, Inc.
• 7.12. CytomX Therapeutics, Inc.
• 7.13. Gilead Sciences, Inc.
• 7.14. Incyte Corp.
• 7.15. Johnson & Johnson Services, Inc.
• 7.16. Jounce Therapeutics, Inc.
• 7.17. MacroGenics, Inc.
• 7.18. Novartis AG
• 7.19. Merck & Co., Inc.,
• 7.20. Xencor, Inc.
• 7.21. Ziopharm Oncology, Inc.